Beyond the brain: widespread pathology in Huntington's disease

@article{Burg2009BeyondTB,
  title={Beyond the brain: widespread pathology in Huntington's disease},
  author={Jorien M. M. van der Burg and Maria Bj{\"o}rkqvist and Patrik Brundin},
  journal={The Lancet Neurology},
  year={2009},
  volume={8},
  pages={765-774}
}

Figures from this paper

Metabolism in Huntington's disease: a major contributor to pathology.
TLDR
It is only conceivable that combinatorial therapies aiming for neuronal protection in consort with metabolic upliftment will prove to be more efficient than the existing symptomatic treatment options.
A New Perspective on Huntington’s Disease: How a Neurological Disorder Influences the Peripheral Tissues
TLDR
This review focuses on the current knowledge of peripheral tissue effects in HD animal and cell experimental models and identifies biomarkers and mechanisms involved or affected in the progression of the disease as new therapeutic or early diagnostic options.
H05 Gene expression profile in fibroblasts of Huntington's disease patients and controls
TLDR
This study allowed them to evidence the modulation at the transcriptional level of a discrete number of genes relevant in biological processes which are altered in the disease—processes such as transcription and its regulation, apoptosis, regulation of actin cytoskeleton, inositol phosphate metabolism and vesicle mediated transport.
The role of immunity in Huntington's disease
TLDR
A novel understanding is brought to the interaction of the immune system to HD pathology, thereby shedding light on its potential pathogenic role and revisiting the clinical data on the anti-inflammatory drug trials in HD and proposing new experimental approaches to interrogate the role of immunity.
Huntington’s Disease: An Update
TLDR
The review aims majorly on the history, etiology, symptoms, pathophysiology, treatment and other aspects of Huntington’s disease.
Clinical Features of Huntington's Disease.
TLDR
The epidemiology, genetics and pathogenesis of HD as well as the clinical presentation and management of HD, which is currently focused on symptomatic treatment are discussed.
Neurotoxicity in Huntington Disease
TLDR
The aetiology of HD is well established however the understanding of the pathogenesis is still evolving, and mutation in the HTT gene confers neurotoxicity on multiple levels, ranging from the genetic/protein level, intracellular level, intercellular level, to the end-organ level.
...
...

References

SHOWING 1-10 OF 117 REFERENCES
Weight changes in Huntington's disease
TLDR
It is confirmed that Huntington’s disease patients have lower body mass indexes compared with controls and that male patients gained significantly less weight compared with male controls, with this change becoming increasingly marked with disease progression.
Hypothalamic–endocrine aspects in Huntington's disease
TLDR
Investigating neuroendocrine changes in HD opens up the possibility of finding biomarkers to evaluate future therapies for HD, as well as of identifying novel targets for therapeutic interventions.
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
TLDR
The peripheral immune system was examined and found widespread evidence of innate immune activation detectable in plasma throughout the course of HD, suggesting parallel central nervous system and peripheral pathogenic pathways of immune activation in HD.
Orexin loss in Huntington's disease.
TLDR
The results show that the loss of orexin is a novel and potentially very important pathology in HD and could be used as a biomarker reflecting neurodegeneration.
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease
  • C. Saft, J. Zange, L. Schöls
  • Biology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2005
TLDR
It is found that oxidative function is impaired to a similar extent in manifest HD patients and asymptomatic mutation carriers and this suggests that mitochondrial dysfunction is an early and persistent component of the pathophysiology of HD.
Formation of polyglutamine inclusions in non-CNS tissue.
TLDR
The formation of inclusions in non-CNS tissues will be particularly useful with respect to in vivo monitoring of pharmaceutical agents selected for their ability to prevent polyglutamine aggregation in vitro, without the requirement that the agent can cross the blood-brain barrier in the first instance.
Normal huntingtin function: an alternative approach to Huntington's disease
TLDR
There is considerable evidence that normal huntingtin is important for neuronal function and that the activity of some of its downstream effectors, such as brain-derived neurotrophic factor, is reduced in Huntington's disease.
Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
TLDR
Common gene expression changes in skeletal muscle from R6/2 mice, Hdh(CAG(150)) homozygous knock-in mice and HD patients are identified and it is raised the possibility that muscle gene expression may be used as an objective biomarker to complement clinical HD-rating systems.
...
...